A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR
Latest Information Update: 08 Aug 2023
At a glance
- Drugs Tropifexor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms FLIGHT-FXR
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Jun 2023 Results analyzing changes inliver fibrosis and individual septa parameters over time in ahomogenous, well-characterised group of patients with NASH F3 fibrosis stage; by deriving biopsy from this study, presented at the European Association for the Study of the Liver Congress 2023
- 15 Jun 2023 According to a HistoIndex media release, post hoc analysis data from this study were recently published in Nature Medicine.
- 15 Jun 2023 Results presented in a HistoIndex media release.